Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics

Abstract

Abstract. The development and progression of cancer is a complex and multifactorial process and the global prevalence of obesity is markedly increasing. A number of studies have made an association between obesity and increased rates of epithelial tumors. Obesity is associated with altered adipokine levels, potentially contributing to the process of tumor development and metastasis. In the current study, the associations between circulating adipokines and measures of adiposity and tumor characteristics among patients diagnosed with solid malignancies were examined at the time of presentation, and following the administration of chemotherapy. A total of 30 patients with cancer and matched healthy controls were enrolled in the present study. Plasma adipokine levels of hepatocyte growth factor (HGF), adiponectin and leptin were determined using commercially available ELISA kits. At baseline, plasma HGF, adiponectin and leptin levels were not significantly different between patients with cancer and the healthy controls. Circulating HGF levels were significantly associated with the stage of cancer at diagnosis (P=0.044), but lacked a significant association with lymph node status (P=0.194). Plasma adiponectin and leptin levels were not significantly associated with tumor characteristics at the time of diagnosis. Only leptin was positively correlated with the body mass index of patients with cancer (P<0.001). No significant correlations were detected between the evaluated adipokines and measures of visceral obesity, as determined by waist circumference and the waist-hip ratio at presentation. Following administration of chemotherapy, adiponectin was the only adipokine evaluated in the current study that exhibited a significant difference, when compared with baseline plasma levels (P= 0.013), and a significant positive correlation between baseline and follow-up circulating levels (P=0.002) among patients with cancer. In addition, there were no significant inter-correlations between circulating adipokines at baseline level and during follow-up in patients with cancer. Collectively, the findings of the current study suggest a lack of diagnostic roles for the adipokines investigated and no significant association with measures of adiposity. Adiponectin may be a potential adipokine to measure in patients with cancer, in order to further assess its prognostic and predictive potential. IntroductionCancer is a major public health problem and is a leading cause of mortality worldwide (1). Annual cancer cases are predicted to rise from 14 million in 2012 to 22 million within the next two decades (2). In Jordan, there has been a notable increase in the incidence and burden of cancer and, according to the most recent report from the Jordan National Cancer Registry, the number of new cancer cases diagnosed among Jordanians increased by ~46% from 2000-2012 (3). The most common types of cancer among Jordanian patients were breast, colorectal, lung, lymphoma and urinary bladder cancer (3). At present, epidemiological and experimental...

Leptin stimulates the epithelial‑mesenchymal transition and pro‑angiogenic capability of cholangiocarcinoma cells through the miR‑122/PKM2 axis

“…An increasing body of evidence supports the association between obesity and a higher risk of developing different types of cancer (25,26). In a study on 30 patients with colorectal, breast, lung, testicular or gastric cancer, no significant differences were observed in the serum leptin level at baseline or in response to chemotherapy between patients and matched healthy controls, although leptin was identified to be positively associated with the body mass index of patients (27). By contrast, when focusing on a specific type of cancer, several studies suggest a positive association between higher serum leptin level and cancers (28,29), while some suggest a negative correlation (11,30).…”

Altered Serum Marker of Adipokines Profile in Breast Cancer Women

“…Insulin may upregulate the expression of vascular endothelial growth factor (VEGF), a potent angiogenic agent that is secreted by breast cancer cells, may synergize with the mitogenic effects of estrogen. Adiponectin inversely correlated with estrogen levels may effect breast cancer risk by altering circulating estrogen levels Chemerin, also known as retinoic acid receptor responder 2 (RARRES2) encoded by the RARRES2 gene is a newly identified adipokinesecreted by adipose tissue characterized as a potent chemoattractant protein (21) .known for its roles in adipogenesis, angiogenesis, skin function, metabolic activity, and, recently, tumorigenesis (22) .Chemerin derived peptides plays a crucial role in regulation of immune response, insulin resistance, and adipose maturation, differentiation, and metabolism as well as exhibits both pro-inflammatory and anti-inflammatory effects, that may be involved in both initiation and resolution of inflammation (23,24) ,chemerin as a chemoattractant protein may contribute to recruitment of macrophages into adipose tissue and has a role at an early stage of adipose tissue inflammation.…”

Differentially expressed genes SNRPC and PRPF38A are potential biomarkers candidates for osteosarcoma

“…Some of these protein interact with SNRPC (38). Pre-mRNA splicing factor 38A (PRPF38A), is a center of spliceosome component, which is related to protein-protein interaction (42).…”